Use of severe combined immunodeficient (SCID) mice to produce human hybridoma ascites.
The use of the severe combined immunodeficient mouse (SCID), CB-17/Icr//Imd-SCID, was investigated for the production of human hybridoma ascites containing human antibody. Human-human hybridomas, generated from the fusion of lymphocytes isolated from regional draining lymph nodes of cancer patients with the SHFP-1 fusion partner, were injected i.p. at various cell concentrations into pristane-primed SCID mice. Ascites growth was typically observed at 7-14 days postinoculation. No significant differences in ascites yield or production were observed between IgG- and IgM-secreting hybridomas. Yields of immunoreactive human immunoglobulin ranged from approximately 0.5 to 3 mg/ml of harvested ascites. The ease and relatively low cost suggest that the use of SCID mice is preferred over conventional and costly large-scale industrial procedures.
McKnight
M E
ME
Sci-Clone, Inc., San Diego, CA 92126.
Prather
K
K
Koda
K
K
DeBoer
K F
KF
Glassy
M C
MC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D001202:Ascitic Fluid / Q000166:cytology / Q000276:immunology*; D005260:Female; D006801:Humans; D006825:Hybridomas / Q000276:immunology*; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D008297:Male; D051379:Mice; D016513:Mice, SCID
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007075:Immunoglobulin M